Key found to kill cystic fibrosis superbug

Researchers from the Schulich School of Medicine & Dentistry at The University of Western Ontario , working with a group from Edinburgh, have discovered a way to kill the cystic fibrosis superbug, Burkholderia cenocepacia.

These investigators, under the leadership of Dr. Miguel Valvano, Department of Microbiology and Immunology, have had their research published in the May issue of the Journal of Bacteriology, and highlighted in Nature Reviews/Microbiology.

B. cenocepacia is a multi-drug resistant microorganism that lives in damp or wet places and causes rot in plants such as onions. While it rarely causes infection in healthy people, it can be fatal for people with cystic fibrosis (CF), an inherited disease where the lungs become clogged with thick mucus, often leading to chronic respiratory infections.

The team of researchers has identified a weakness in the armour that protects the B. cenocepacia bacterium from the effects of antibiotics. They hypothesize that preventing the synthesis of a key sugar required for this armour, 4-amino-4-deoxy-L-arabinose (Ara4N), may lead to a susceptibility within the cell membrane to antibiotics.

"We are very excited with these findings, as they will let us come up with novel molecules to disrupt the making of Ara4N," says Valvano. "These molecules could then be tested as novel antibiotics." Valvano is a Professor and Chair of the Department of Microbiology and Immunology, a Canada Research Chair in Infectious Diseases and Microbial Pathogenesis, and leader of the Infectious Diseases Research Group at the Siebens-Drake Research Institute.

"We're delighted by this news," says Cathleen Morrison, CEO of the Canadian Cystic Fibrosis Foundation. "The possibility of a life-saving antibiotic to fight B. cenocepacia is tremendously encouraging to adults and children who have cystic fibrosis."

Dr. Bhagirath Singh, Scientific Director of the CIHR Institute of Infection and Immunity, says "This discovery provides new hope for the eradication of these bugs from cystic fibrosis patients and to improve their quality of life by developing new treatments."

Source: Canadian Institutes of Health Research

Related stories:

Breaking the 'mucus barrier' with a new drug delivery system
Chemical engineers from Johns Hopkins University have broken the "mucus barrier," engineering the first drug-delivery particles capable of passing through human mucus — regarded by many as nearly impenetrable — and carrying medication that could treat a range of diseases. Those conditions include lung cancer, cervical cancer and cystic fibrosis, the research noted in a presentation scheduled for the 236th National Meeting of the American Chemical Society.
Scientists find a novel mechanism that controls the development of autoimmunity
Scientists at the National Institutes of Health have found a mechanism in the immune systems of mice that can lead to the development of autoimmune disease when turned off. The findings shed light on the processes that lead to the development of autoimmunity and could also have implications for the development of drugs to increase the immune response in diseases such as cancer and HIV. The study paper appears online today in the journal Nature.
Scientists race to stay ahead of the drug-taking and genetic manipulation that threatens sport
The race to ensure that scientists stop drug-taking athletes from damaging sport by using performance enhancing drugs or undergoing genetic manipulation is a constant challenge, according to a major four-decade review by three of the World's leading experts on doping in sport.
Mucous breakthrough in mice holds promise for cystic fibrosis
A London, Canada scientist studying cystic fibrosis (CF) has successfully corrected the defect which causes the overproduction of intestinal mucous in mice. This discovery by Dr. Richard Rozmahel, a scientist with the Lawson Health Research Institute, affiliated with The University of Western Ontario, has clear implications to understanding and treating this facet of the disease in humans. CF is a fatal, genetic disease characterized by an overproduction of mucous in the lungs and digestive system.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
Researchers discover cell's 'quality control' mechanism
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells – sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
Consortium develops new method enabling routine targeted gene modification
A multi-institutional team led by Massachusetts General Hospital (MGH) investigators has developed a powerful new tool for genomic research and medicine – a robust method for generating synthetic enzymes that can target particular DNA sequences for inactivation or repair. In the July 25 issue of Molecular Cell, the researchers describe an efficient, publicly available method to engineer customized zinc-finger nucleases (ZFNs), which can be used to induce specific genomic modifications in many types of cells.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine. The robust method will allow researchers to generate synthetic enzymes that can target and manipulate DNA sequences for inactivation or repair.

News discussion:

Medicine & Health news